KR102845326B1 - Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태 - Google Patents

Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태

Info

Publication number
KR102845326B1
KR102845326B1 KR1020217009437A KR20217009437A KR102845326B1 KR 102845326 B1 KR102845326 B1 KR 102845326B1 KR 1020217009437 A KR1020217009437 A KR 1020217009437A KR 20217009437 A KR20217009437 A KR 20217009437A KR 102845326 B1 KR102845326 B1 KR 102845326B1
Authority
KR
South Korea
Prior art keywords
compound
exhibits
peaks
xrpd
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217009437A
Other languages
English (en)
Korean (ko)
Other versions
KR20210054546A (ko
Inventor
넬슨 비. 올리비에
키란 레디
가브리엘 마르티네즈 보텔라
매그너스 론
폴 에이. 라스카
Original Assignee
프락시스 프리시젼 메디신즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프락시스 프리시젼 메디신즈, 인크. filed Critical 프락시스 프리시젼 메디신즈, 인크.
Publication of KR20210054546A publication Critical patent/KR20210054546A/ko
Application granted granted Critical
Publication of KR102845326B1 publication Critical patent/KR102845326B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
KR1020217009437A 2018-08-31 2019-08-30 Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태 Active KR102845326B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725805P 2018-08-31 2018-08-31
US62/725,805 2018-08-31
US16/517,369 2019-07-19
US16/517,369 US10562930B1 (en) 2018-08-31 2019-07-19 Salts and crystal forms of GABAA positive allosteric modulator
PCT/US2019/049103 WO2020047434A1 (en) 2018-08-31 2019-08-30 Salts and crystal forms of gabaa positive allosteric modulator

Publications (2)

Publication Number Publication Date
KR20210054546A KR20210054546A (ko) 2021-05-13
KR102845326B1 true KR102845326B1 (ko) 2025-08-12

Family

ID=69528249

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009437A Active KR102845326B1 (ko) 2018-08-31 2019-08-30 Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태

Country Status (13)

Country Link
US (4) US10562930B1 (https=)
EP (2) EP3710465B1 (https=)
JP (3) JP7199739B2 (https=)
KR (1) KR102845326B1 (https=)
CN (1) CN113473991B (https=)
AU (1) AU2019333310B8 (https=)
BR (1) BR112021003727A2 (https=)
CA (1) CA3111193A1 (https=)
IL (1) IL281143B2 (https=)
MA (1) MA50921A (https=)
MX (1) MX2021002382A (https=)
TW (2) TWI823999B (https=)
WO (1) WO2020047434A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117024501A (zh) * 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
EP4294819A4 (en) 2021-02-18 2024-12-18 Praxis Precision Medicines, Inc. GABA-A POSITIVE ALLOSTERIC MODULATOR HEMI-CITRATE SALTS AND CORRESPONDING CRYSTALLINE FORM
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
WO2022231309A1 (ko) 2021-04-27 2022-11-03 경북대학교 산학협력단 저분자 콜라겐을 유효성분으로 포함하는 근감소증의 예방 또는 개선용 식품 조성물 및 약학적 조성물
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023164386A1 (en) * 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
EP4514357A4 (en) * 2022-04-26 2026-04-29 Praxis Prec Medicines Inc METHODS OF TREATING NEUROLOGICAL DISORDERS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131392A1 (en) 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
ATE284895T1 (de) * 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
CN1688288A (zh) * 2002-08-05 2005-10-26 巴克斯特国际公司 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
WO2005007600A2 (en) 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
AU2004265101B2 (en) 2003-08-14 2009-06-11 F. Hoffmann-La Roche Ag Gabanergic modulators
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
MX2011011156A (es) * 2009-04-23 2011-11-04 Theravance Inc COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
CA2789654A1 (en) * 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
US20140315992A1 (en) 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
HRP20180487T1 (hr) 2013-07-24 2018-05-04 Commissariat à l'énergie atomique et aux énergies alternatives Upotreba flekainida kao anti-koneksinskog sredstva i metoda za potenciranje učinaka psihotropnog lijeka
WO2016015653A1 (zh) * 2014-08-01 2016-02-04 江苏豪森药业股份有限公司 C-Met抑制剂结晶型游离碱或其结晶型酸式盐及其制备方法和应用
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
MY204493A (en) 2017-11-10 2024-08-30 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
MX2021006985A (es) 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
MX2021007142A (es) 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Compuestos organicos.
US20220125803A1 (en) 2019-03-04 2022-04-28 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause
WO2020185710A1 (en) 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor
US20220265666A1 (en) 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
JP2022552808A (ja) 2019-10-02 2022-12-20 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａ受容体陽性アロステリック調節因子と、ｎｍｄａ拮抗薬、ｎｍｄａ陰性アロステリック調節因子、またはｎｍｄａ部分作動薬との組み合わせ
WO2021168106A1 (en) 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
WO2022006541A1 (en) 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
JP2023539125A (ja) 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP4294819A4 (en) 2021-02-18 2024-12-18 Praxis Precision Medicines, Inc. GABA-A POSITIVE ALLOSTERIC MODULATOR HEMI-CITRATE SALTS AND CORRESPONDING CRYSTALLINE FORM
EP4329751A4 (en) 2021-04-26 2025-03-19 Praxis Precision Medicines, Inc. Methods of treatment with neuroactive steroids
WO2023159094A2 (en) 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
EP4514357A4 (en) 2022-04-26 2026-04-29 Praxis Prec Medicines Inc METHODS OF TREATING NEUROLOGICAL DISORDERS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131392A1 (en) 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
JP2008542419A (ja) * 2005-06-09 2008-11-27 ユーロ−セルティーク エス．エイ． 神経刺激性ステロイドの医薬組成物及びその使用
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
MA50921A (fr) 2020-09-23
US10562930B1 (en) 2020-02-18
TW202024108A (zh) 2020-07-01
BR112021003727A2 (pt) 2021-05-25
AU2019333310A8 (en) 2025-04-17
US20200255471A1 (en) 2020-08-13
TWI850138B (zh) 2024-07-21
EP3710465A4 (en) 2020-09-23
CN113473991A (zh) 2021-10-01
EP3710465B1 (en) 2024-08-14
IL281143A (en) 2021-04-29
US20220024967A1 (en) 2022-01-27
AU2019333310B2 (en) 2024-11-21
US20200071350A1 (en) 2020-03-05
EP3710465A1 (en) 2020-09-23
JP2025020120A (ja) 2025-02-12
EP4458357A2 (en) 2024-11-06
KR20210054546A (ko) 2021-05-13
US10927141B2 (en) 2021-02-23
JP2021504297A (ja) 2021-02-15
JP7199739B2 (ja) 2023-01-06
EP4458357A3 (en) 2024-12-18
TWI823999B (zh) 2023-12-01
TW202408461A (zh) 2024-03-01
US20240140985A1 (en) 2024-05-02
AU2019333310A1 (en) 2021-04-08
CA3111193A1 (en) 2020-03-05
US12404297B2 (en) 2025-09-02
IL281143B2 (en) 2025-04-01
WO2020047434A1 (en) 2020-03-05
IL281143B1 (en) 2024-12-01
AU2019333310B8 (en) 2025-04-17
JP2023036708A (ja) 2023-03-14
MX2021002382A (es) 2021-08-11
CN113473991B (zh) 2025-12-26

Similar Documents

Publication Publication Date Title
KR102845326B1 (ko) Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태
US11434226B2 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
CN114773211B (zh) 一种葡甲胺盐的晶型、其制备方法及应用
AU2006210810B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
BR112020006051A2 (pt) formas cristalinas de lenalidomida
HK40118203A (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178B (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178A (en) Salts and crystal forms of gabaa positive allosteric modulator
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
CN120172972A (zh) 咪唑并[1,2-a]吡啶类化合物的盐或其多晶型
EP2154137A1 (en) Crystalline form of moxifloxacin base
HK40062038B (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)